(Image source: Everyday Health)
Overview:
Rykindo belongs to a class of drugs called Antipsychotics, 2nd Generation; Antimanic Agents. It is used for the treatment of schizophrenia in adults and as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RYKINDO is not approved for use in patients with dementia-related psychosis.
Medicinal Uses:
It is used for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
Side Effects:
Falls
Leukopenia, Neutropenia, and Agranulocytosis
Potential for cognitive and motor impairment
Seizures
Dysphagia
Priapism
Body temperature dysregulation
Osteodystrophy and tumors in animals
Paradoxical reactions:
The most common adverse reactions in patients with schizophrenia (≥ 5%) were headache, parkinsonism, dizziness, akathisia, fatigue, constipation, dyspepsia, sedation, weight increase, pain in the extremity, and dry mouth.
The most common adverse reactions in patients with bipolar disorder were (5% in monotherapy trial) weight increase and (≥ 10% in adjunctive therapy trial) tremors and parkinsonism.
Drug Interactions:
Please be aware that drug interaction could increase the risk for serious side effects, so please make a list of all drugs/medicines you use and share it with your doctor and pharmacist.
Drugs listed below can cause drug interactions with Rykindo:
Tea
Cola
Alcohol
acetaminophen/hydrocodone
buprenorphine
Celexa (citalopram)
Dosage:
Recommended dosage of RYKINDO is 25 mg intramuscular (IM) every 2 weeks. Patients not responding to 25 mg may benefit from 37.5 mg or 50 mg. Dosage titration should not be made more frequently than every 4 weeks. The maximum recommended dosage should not exceed 50 mg every 2 weeks. Patients should establish tolerability with oral risperidone prior to initiating treatment with RYKINDO.
Note:
In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. Cardiovascular monitoring should commence immediately and include continuous electrocardiographic monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of QT-prolonging effects that might be additive to those of risperidone. Similarly, it is reasonable to expect that the alpha-blocking properties of bretylium might be additive to those of risperidone, resulting in problematic hypotension.
Citation:
CUNHA, JOHN P. "RYKINDO." RxList, 26 Jan. 2023, www.rxlist.com/rykindo-drug.htm.
Drugs.com. "Rykindo Interactions." Drugs.com, www.drugs.com/drug-interactions/risperidone,rykindo.html. Accessed 24 Mar. 2023.
RYKINDO® (risperidone) for extended-release injectable suspension, for intramuscular use . www.accessdata.fda.gov/drugsatfda_docs/label/2023/212849s000lbl.pdf.
Upham, Becky. "FDA Approves Rykindo, a Long-Lasting Injectable, for Schizophrenia and Bipolar I." EVERYDAY HEALTH, 18 Jan. 2023, www.everydayhealth.com/bipolar-disorder/fda-approves-rykindo-a-long-lasting-injectable-for-schizophrenia-and-bipolar-i/.
Comments